|
| Press Releases |
|
 |
|
| Wednesday, November 26, 2025 |
|
|
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status |
| Eisai Co., Ltd. and Biogen Inc. announced today that Eisai has completed the rolling submission of the Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: LEQEMBI(R)) subcutaneous autoinjector (SC-AI), LEQEMBI IQLIK, as a weekly starting dose after the FDA granted Fast Track Status. more info >> |
|
| Monday, November 17, 2025 |
|
|
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI(R)" (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. more info >> |
|
| Thursday, October 30, 2025 |
|
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma |
| more info >> |
|
| Tuesday, October 28, 2025 |
|
|
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma |
| more info >> |
|
| Monday, October 27, 2025 |
|
|
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease |
| more info >> |
|
| Tuesday, October 14, 2025 |
|
|
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025" |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that LEQEMBI(R) IQLIK(TM), a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer's disease (AD) has been selected by TIME as one of the "Best Inventions of 2025" in the Medical and Healthcare category. more info >> |
|
| Wednesday, October 8, 2025 |
|
|
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that lecanemab-irmb subcutaneous injection (U.S. brand name: LEQEMBI(R) IQLIK(TM) is now available in the U.S. as a maintenance dosing regimen for the treatment of Alzheimer's disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). more info >> |
|
| Friday, October 3, 2025 |
|
|
Eisai Highlights Breadth of Oncology Research at ESMO 2025 |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the presentation of clinical research across its oncology portfolio and pipeline during the European Society for Medical Oncology (ESMO) Congress 2025, which is taking place in Berlin, Germany from October 17 to 21. more info >> |
|
| Monday, September 29, 2025 |
|
|
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI(R)" (generic name: lecanemab) has been approved for once every four weeks intravenous (IV) maintenance dosing by the National Medical Products Administration (NMPA) in China. more info >> |
|
| Wednesday, September 24, 2025 |
|
|
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia |
| Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that the Therapeutic Goods Administration (TGA) of Australia has approved the humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI(R)" (brand name, generic name: lecanemab) for mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease (AD) (collectively referred to as early AD) in adults who are either ApoEε4* non-carriers or heterozygous carriers. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
隨著歐洲與東南亞吸納越來越多國際護理人員，全球護理人員遷徙模式正發生轉變
Apr 28, 2026 22:00 HKT/SGT
|
|
|
随着欧洲和东南亚吸纳的国际护士比例不断上升，全球护士流动格局正在发生变化
Apr 28, 2026 22:00 HKT/SGT
|
|
|
Global Nurse Migration Patterns Shift as Europe, Southeast Asia Absorb Growing Share of International Nurses
Apr 28, 2026 22:00 HKT/SGT
|
|
|
Tenstorrent、新たなネットワーク型AIアーキテクチャ上で展開される業界最高水準の性能により大規模AIを実現
Apr 28, 2026 22:00: JST
|
|
|
Tenstorrent Enables AI At Scale with Industry-Leading Performance Deployed on Novel Networked AI Architecture
Apr 28, 2026 21:00 HKT/SGT
|
|
|
TANAKA to Showcase Advanced Semiconductor Materials and Circular Economy Initiatives at SEMICON Southeast Asia 2026
Apr 28, 2026 21:00 JST
|
|
|
HKTDC's response to Hong Kong's export figures for March
Apr 28, 2026 19:23 HKT/SGT
|
|
|
CanSinoBIO Delivers Q1 Revenue Growth Amid Accelerating International Expansion
Apr 28, 2026 19:11 HKT/SGT
|
|
|
康希諾生物一季度業績穩健增長 全生命週期佈局打開長期價值空間
Apr 28, 2026 19:04 HKT/SGT
|
|
|
Kincora Commences Drilling at the Historic Condobolin Mining Field
Apr 28, 2026 19:00 HKT/SGT
|
|
|
由美國馬球協會（U.S. Polo Assn.）與 ESPN 共同贊助的「美國公開馬球錦標賽(R)」決賽圓滿落幕，為本季創下多項紀錄的美國馬球賽季畫下句點
Apr 28, 2026 19:00 HKT/SGT
|
|
|
由美国马球协会（U.S. Polo Assn.）和ESPN联合呈现的著名美国公开马球锦标赛（U.S. Open Polo Championship(R)）决赛，为这个创下多项纪录的美国马球赛季画上了句号
Apr 28, 2026 19:00 HKT/SGT
|
|
|
The Prestigious U.S. Open Polo Championship(R) Final Closes a Record-Breaking American Polo Season, Supported by U.S. Polo Assn. and ESPN
Apr 28, 2026 19:00 HKT/SGT
|
|
|
康希诺生物一季度业绩稳健增长 全生命周期布局打开长期价值空间
Apr 28, 2026 18:58 HKT/SGT
|
|
|
NEC Launches "Africa Corporate Innovation Program" Accelerating Business Through Co-Creation with African Startups
Apr 28, 2026 19:05 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
